UPDATE: On January 8, 2021, the Supreme Court of Canada dismissed Janssen’s application for leave to appeal (Docket No. 39099) (see article here).
On March 30, 2020, Kennedy and Janssen applied to the Supreme Court of Canada for leave to appeal a Federal Court of Appeal decision relating to Kennedy’s patent covering uses of REMICADE (infliximab) and Hospira’s biosimilar, INFLECTRA: SCC Docket No. 39099. As previously reported, the Federal Court of Appeal overturned certain findings of infringement (relating to certain dependent claims and separately, Celltrion) and remanded the issues of obviousness and anticipation to the trial judge for reconsideration: Hospira Healthcare Corporation v Kennedy Trust for Rheumatology Research, 2020 FCA 30.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Canada releases Statement on Implementation for the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP)
On October 17, 2020, the Government of Canada published a Statement on Implementation for the Comprehensive and Progressive Agreement for Trans-Pacific Partnership.Read More -
2020 Highlights in Canadian Life Sciences IP and Regulatory Law
In 2020, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law.Read More -
COVID-19 Update: CIPO, Federal Courts, Health Canada
[Last updated on February 26, 2021] In view of COVID-19, we have compiled a list of important updates as it relates to the pandemic and its impact on Life Sciences.Read More